Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

Next Previous
X
Search
Trial Profile

Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Asparaginase; Busulfan; Ciclosporin; Ciclosporin; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Methotrexate; Mitoxantrone
  • Indications Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Jan 2024 Results from COG-AAML03P1 and COG-AAAML0531, analyzing genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML, published in the Clinical Cancer Research
    • 01 Aug 2022 LASSO regression modeling was used to develop a 10-gene DNA damage response gene expression score (CalDDR-GEx10) predictive of clinical outcome in pediatric AML patients treated with treatment regimen containing GO from the AAML03P1 and AAML0531 trials, published in the Leukemia.
    • 18 Mar 2022 Genomic data of patients from two studies (AAML03P1 and AAAML0531 trials) were used to assess the pharmacogenomic impact of SNPs in DNA damage response (DDR) pathway genes on response to GO treatment, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top